Top Markets
#1 PulseChain PulseChain +45.13%
#2 Glidr Glidr +11.05%
#3 Fake World Assets Fake World Assets +9.47%
#4 Meteora Meteora +7.99%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +6.90%
#6 eCash eCash +6.72%
#7 Qkacoin Qkacoin +6.49%
#8 OPENLOOT OPENLOOT +5.89%
#9 Velvet Velvet +5.57%
#10 Tornado Cash Tornado Cash +5.56%
Coin of the day
PulseChain PulseChain
Innstillinger
Språk
NORSK
Valuta
USD
Tema
LAUNXP Biomedical Co., Ltd LAUNXP Biomedical Co., Ltd

LAUNXP Biomedical Co., Ltd

6876
Rangering i aksjer #28462
LAUNXP Biomedical Co. Ltd. specializes in developing innovative pharmaceutical... LAUNXP Biomedical Co. Ltd. specializes in developing innovative pharmaceutical treatments for various types of cancer. Their product line includes therapies designed to combat tumor growth and inhibit cell proliferation, notably utilizing advanced platforms such as virus-like nanoparticles and other nanoparticle-based drug delivery systems. The company was established on September 24, 2015, and its primary corporate operations are based in Taichung, Taiwan.
Aksjekurs
$0.38317829
Markedsverdi
$26.52M
Endring (1 dag)
-3.60%
Endring (1 år)
-50.60%
Land
TW
Handel LAUNXP Biomedical Co., Ltd (6876)

Kategori

Healthcare
Inntekter for LAUNXP Biomedical Co., Ltd (6876)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til LAUNXP Biomedical Co., Ltd er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for LAUNXP Biomedical Co., Ltd fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH